Navigation Links
Rosetta Genomics Announces Three New Diagnostic Tests to Enter Development
Date:6/18/2008

New Development Programs to Include Response Prediction to Ovarian Cancer

Treatment, Predicting Risk of Gastric Cancer Recurrence, and

Differentiation of Small Cell From Non-Small Cell Lung Cancer In Addition, the Company has Identified Unique microRNA Biomarkers in the Serum of Colon Cancer Patients, Which may Serve as the Basis for a Future

Test for Colon Cancer New Tests Expected to be Developed and Marketed Through the Company's Clinical Laboratory Improvement Act (CLIA) Certified Laboratory, for Which

a Binding Acquisition Term Sheet has Recently Been Signed

REHOVOT, Israel and JERSEY CITY, New Jersey, June 18 /PRNewswire-FirstCall/ -- Rosetta Genomics Ltd. (Nasdaq: ROSG), a leader in the development of microRNA-based diagnostics and therapeutics, announced today the advancement of three new diagnostic tests into its development pipeline. The Company expects to develop and market the new tests through its own CLIA-certified laboratory, for which the Company recently signed a binding acquisition term sheet.

"We aim to be the leading high-complexity molecular diagnostics company, and we believe we have fine-tuned our product engine. This engine is now capable of producing a stream of products that answer unmet medical needs," said Amir Avniel, CEO and President of Rosetta Genomics. "We believe that by the end of 2009, we will have established a prominent position in the oncology and women's health fields."

Leveraging unique microRNA biomarkers identified using Rosetta Genomics' proprietary microRNA extraction and quantification methods, the new programs will focus on the following indications, which are expected to be clinically available during 2009-201
'/>"/>

SOURCE Rosetta Genomics Ltd
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4 5

Related biology technology :

1. Rosetta Genomics Announces Annual General Meeting of Shareholders to be Held on September 24, 2007
2. NYU Medical Center Collaborates With Rosetta Genomics to Develop a microRNA-Based Diagnostic Test for Melanoma
3. Rosetta Genomics to Present at the American Association of Cancer Research (AACR) "Molecular Diagnostics in Cancer Therapeutic Development" Conference
4. Rosetta Genomics to Webcast Presentation at Maxim Group Growth Conference
5. Rosetta Genomics to Host and Webcast its R&D Day on Friday, October 26, 2007
6. Rosetta Genomics Will Host and Webcast its R&D Day on Friday, October 26, 2007
7. Rosetta Genomics Announces Initiation of In Vivo Studies Following Successful Completion of First Milestone in MicroRNA-based Therapeutic Program for Liver Cancer
8. Rosetta Genomics Selects PCR as Platform for its microRNA-based Diagnostics to be Launched in 2008, Licensed Nanogens MGB Probe Technology
9. Rosetta Genomics and Columbia University Medical Center to Develop MicroRNA-based Diagnostics for Leukemia and Non Hodgkin Lymphoma
10. Rosetta Genomics Announces Initiation of Expansion of US Operations to Facilitate Expected Product Launches in 2008
11. Henry Ford Hospital and Rosetta Genomics to Develop MicroRNA-based Diagnostics for Brain Cancer

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/5/2009)...Nov. 5 SpineSmith Partners has sig...-develop a unique scaffold that mimics the structu...on of several commercial products by SpineSmith,s ...elieves the GenOsteo scaffold represents a signifi...ue and ideal environment for the delivery of adult...
(Date:11/5/2009)... LASIK Surgery and vision correction experts l... actively involved at the recently concluded Ameri...ting in San Francisco, California. Dr. Stephen Bri...n Davidorf, MD, Dr. Peter Rapoza, MD, Dr. Michael ...Bowman, MD, Dr. Edward Manche, MD, and Dr. Parag M...
(Date:11/4/2009)... The Human Anthrax Vaccine Program must be sto...feature film "A Call to Arms:2009 Edition&quo...atal Immunity: The Human Anthrax Vaccine Story&quo...t danger of top secret government science turned i...untability to its victims. It is available for wo...
(Date:11/4/2009)...ILLE, Md., Nov. 4 Zyngenia, Inc., ...n next-generation antibody drug development, today...es A funding from New Enterprise Associates (NEA),... The capital will be used to create novel, multi-s...r more biological targets with a single agent. The...
Breaking Biology Technology:SpineSmith Partners and GenOsteo Announce Collaborative Product Development Agreement 2Leading Vision Correction Experts in Trusted LASIK Surgeons Directory Educate Fellow Doctors at AAO Annual Meeting 2Leading Vision Correction Experts in Trusted LASIK Surgeons Directory Educate Fellow Doctors at AAO Annual Meeting 3Leading Vision Correction Experts in Trusted LASIK Surgeons Directory Educate Fellow Doctors at AAO Annual Meeting 4Leading Vision Correction Experts in Trusted LASIK Surgeons Directory Educate Fellow Doctors at AAO Annual Meeting 5Leading Vision Correction Experts in Trusted LASIK Surgeons Directory Educate Fellow Doctors at AAO Annual Meeting 6Leading Vision Correction Experts in Trusted LASIK Surgeons Directory Educate Fellow Doctors at AAO Annual Meeting 7Leading Vision Correction Experts in Trusted LASIK Surgeons Directory Educate Fellow Doctors at AAO Annual Meeting 8Leading Vision Correction Experts in Trusted LASIK Surgeons Directory Educate Fellow Doctors at AAO Annual Meeting 9Scott Miller's 'A Call To Arms' And 'Fatal Immunity' Are Available For World-Wide Licensing 2Scott Miller's 'A Call To Arms' And 'Fatal Immunity' Are Available For World-Wide Licensing 3Scott Miller's 'A Call To Arms' And 'Fatal Immunity' Are Available For World-Wide Licensing 4Scott Miller's 'A Call To Arms' And 'Fatal Immunity' Are Available For World-Wide Licensing 5Scott Miller's 'A Call To Arms' And 'Fatal Immunity' Are Available For World-Wide Licensing 6Scott Miller's 'A Call To Arms' And 'Fatal Immunity' Are Available For World-Wide Licensing 7Zyngenia, Inc. Raises $10 Million in Series A Funding 2Zyngenia, Inc. Raises $10 Million in Series A Funding 3Zyngenia, Inc. Raises $10 Million in Series A Funding 4
... PAREXEL International,Corporation (Nasdaq: PRXL ...anization, today announced the successful completi...tional Clinical Research Co., Ltd. ("APEX") in,a s...uisition and other,factors discussed herein, the C...uidance for the first quarter of Fiscal Year 2008 ...
... Sept. 26 InterMune, Inc.,(Nasdaq: ITMN ) today ...025,000 shares of common stock at a price to the p...s of common stock, representing the exercise,by th...nal shares in the,offering. The net proceeds to th...million, after payment of underwriting discounts a...
...., Sept. 26 Corium International,Inc., a privatel...nounced,that it has completed a $25.1 million Seri...res. Quantum Technology Partners, Aphelion Capital... round. In connection with,the financing, StrataGe...Ventures portfolio company focused on needle-free ...
Other Biology Technology:PAREXEL International Updates Financial Guidance in Conjunction with the Acquisition of APEX International Clinical Research Co., Ltd. and Other Factors 2PAREXEL International Updates Financial Guidance in Conjunction with the Acquisition of APEX International Clinical Research Co., Ltd. and Other Factors 3PAREXEL International Updates Financial Guidance in Conjunction with the Acquisition of APEX International Clinical Research Co., Ltd. and Other Factors 4InterMune Announces Closing of Public Offering of Common Stock 2Corium International, Inc., Announces $40 Million Financing led by Essex Woodlands Health Ventures 2Corium International, Inc., Announces $40 Million Financing led by Essex Woodlands Health Ventures 3Corium International, Inc., Announces $40 Million Financing led by Essex Woodlands Health Ventures 4
(Date:11/6/2009)... Center and the Chinese Academy of Sciences (CAS) ...on Taste and Smell Research. Organized by Monell i...the first international meeting on taste and smell...utive Officer, American Association for the Advanc...e magazine, will open the meeting with a plenary a...
(Date:11/5/2009)...ty have developed synthetic molecules capable of e...-infected cells, as well as to prostate cancer cel...al of the American Chemical Society , could lead t... , The molecules called "antibody-recruiting m...iting molecule targeting prostate cancer" (ARM-P) ...
(Date:11/4/2009)...ant to officially endorse green tea as a cancer pr...its protective effects, including results of a new...a journal of the American Association for Cancer R...cer. , Vassiliki Papadimitrakopoulo, M.D., prof...ad and Neck Medical Oncology at the University of ...
Breaking Biology News(10 mins):Monell Center joins with CAS to host Beijing meeting on taste and smell research 2New synthetic molecules trigger immune response to HIV and prostate cancer 2Does green tea prevent cancer? Evidence continues to brew, but questions remain 2UNC scientists garner new NIH awards for high risk transformative research 10076 1UNC scientists garner new NIH awards for high risk transformative research 10076 2UNC scientists garner new NIH awards for high risk transformative research 10076 3UNC scientists garner new NIH awards for high risk transformative research 10076 4Thomson Reuters Predicts Nobel Laureates 14245 1Thomson Reuters Predicts Nobel Laureates 14245 2Thomson Reuters Predicts Nobel Laureates 14245 3Thomson Reuters Predicts Nobel Laureates 14245 4Thomson Reuters Predicts Nobel Laureates 14245 5Thomson Reuters Predicts Nobel Laureates 14245 6RetireSafe to Senate 3A Stop Proposed Rationing of High Quality Hospital Care Medicare Needs More Physician Hospitals 58219 1RetireSafe to Senate 3A Stop Proposed Rationing of High Quality Hospital Care Medicare Needs More Physician Hospitals 58219 2
.... A hypertension medication called olmesartan med...the arteries that occurs in patients with high blo... Ferrario, M.D., one of the study,s lead investiga... Research Center at Wake Forest University Baptist... the growing evidence for the role of angiotensin ...
...he Smithsonian,s National Zoo have performed the f...s horse ( E. ferus przewalskii ; E. caballus prze...-VAL-skeez. Przewalksi,s horses are a horse specie...xtinct in the wild in 1970. Currently, there are a...oological institutions throughout the world and in...
...nce and technology policymaking capacity of the Wh...ent can better address key issues facing the natio...rity, and the ability of the United States to comp...primary recommendations are that: , The next P...ader to be Assistant for Science and Technology Po...
Other Biology News:Hypertension treatment effective in reversing vascular damage 2First successful reverse vasectomy on endangered species performed at the National Zoo 2First successful reverse vasectomy on endangered species performed at the National Zoo 3White House science office needs upgrade 2White House science office needs upgrade 3
Human SLPI ELISA Kit from R&D Systems
Rabbit Anti-Human OLFM1 Polyclonal Antibody, Unconjugated from Proteintech Group, Inc.
GELase 50X Reaction Buffer from EPICENTRE Biotechnologies
Axl, phospho ELISA development Kit, DuoSet IC Economy Pack from R&D Systems
Biology Products: